Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Moderna (MRNA) PT Lowered to $185 at Morgan Stanley Following EPS
February 23, 2023 12:39 PM ESTMorgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $185.00 (from $205.00) while maintaining a Overweight rating following earnings.
The analyst commented, "4Q22 was generally in-line. 2023 COGS of 35-40% was above expectations and the most notable downside driver in our... More
Moderna (MRNA) Q4 Revenue Tops Consensus
February 23, 2023 7:05 AM ESTModerna (NASDAQ: MRNA) reported Q4 EPS of $3.61, $1.09 worse than the analyst estimate of $4.70. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.05 billion.
2023 Financial Framework
Advance Purchase Agreements (APAs): The Company has COVID vaccine sales of approximately $5 billion currently contracted for... More